Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects
Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
This was a pilot, phase I, two-period, fasting, bioavailability, safety,and pharmacokinetic
study evaluating single dose of i.v. fentanyl (200 µg) and single doses of 2 mL or 3 mL
inhaled AeroLEF (500 µg/mL) delivered by nebulization with the AeroEclipse BAN device
administered in normal healthy non-smoking subjects.